Cervical Cancer

Deutsche BKK to implement routine HPV testing for cervical cancer screening in Europe

Published in Cancer Weekly, February 7th, 2006

Europe's first cervical cancer screening program using routine human papilloma virus (HPV) testing will be implemented by Deutsche BKK, a major public-health insurance provider in central Germany, in partnership with the local gynecologists' association and a regional hospital, announced Digene Corp. (DIGE).

The protocol adopted by BKK requires use of the Digene HPV Test, also marketed as the DNAwithPap Test. It is the only U.S. Food & Drug Administration-approved test for high-risk types of the human papilloma virus, which cause virtually all cases of cervical cancer. The test is approved in the United States for use along with the Pap to screen women age 30 and older,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2006-02-07)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry